SLC6A3 and parkinsonian disorder: Overall, our findings indicated that dual phase 18F-FP-CIT PET can provide equivalent information on overall functional activity and DAT availability compared to a combination of 18F-FDG PET and delayed phase 18F-FP-CIT PET for the differential diagnosis of parkinsonian disorders with a single injection.